EGFR and breast carcinoma: In agreement with the phenomenon observed in sarcoma cells, Pierce and colleagues showed that knocking down of MGAT5 expression, which led to decreased synthesis of galectin-3 ligands in molecules such as the EGFR, interfered with the migratory response of breast cancer cells in response to EGF.